Default: Altex

ISSN: 1868-596X

Journal Home

Journal Guideline

Altex Q1 Unclaimed

Springer International Publishing AG Germany
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Altex is a journal indexed in SJR in Medicine (miscellaneous) and Pharmacology with an H index of 62. It is an CC BY Journal with a Single blind Peer Review review system, and It has a price of 2000 €. The scope of the journal is focused on in vitro methods, alternatives to animal experiments, toxicology, bioethics. It has an SJR impact factor of 0,737 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 0,737.

Type: Journal

Type of Copyright: CC BY

Languages: English

Open Access Policy: Open Access

Type of publications:

Publication frecuency: -

Price

2000 €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Altex

0,737

SJR Impact factor

62

H Index

56

Total Docs (Last Year)

195

Total Docs (3 years)

3067

Total Refs

653

Total Cites (3 years)

176

Citable Docs (3 years)

3.56

Cites/Doc (2 years)

54.77

Ref/Doc

Comments

No comments ... Be the first to comment!

Aims and Scope


In vitro methods Alternatives to animal experiments Toxicology Bioethics



Best articles by citations

An in vitro method for predicting inhalation toxicity of impregnation spray products_Supplementary file

View more

Opportunities for refinement in neuroscience: Indicators of wellness and post-operative pain in laboratory macaques_suppl

View more

The impact of precision uncertainty on predictive accuracy metrics of non-animal testing methods

View more

From 3Rs to 3D: In vitro alternative models for replacement

View more

The impact of precision uncertainty on predictive accuracy metrics of non-animal testing methods_suppl

View more

Organotypic retinal explant cultures as in vitro alternative for diabetic retinopathy studies_suppl

View more

A first vascularized skin equivalent for as an alternative to animal experimentation

View more

3-D nasal cultures: Systems toxicological assessment of a candidate modified-risk tobacco product

View more

Alternatives to the use of fetal bovine serum: human platelet lysates as a serum substitute in cell culture media

View more

Developmental toxicity of thyroid-active compounds in a zebrafish embryotoxicity test

View more

A critique of the EC's expert (draft) reports on the status of alternatives for cosmetics testing to meet the 2013 deadline

View more

Advice on avoiding the Valley of Death: insights from a 3Rs model of aversive and emetic compound identification

View more
SHOW MORE ARTICLES

State of the art on alternative methods to animal testing from an industrial point of view: Ready for regulation?

View more

A human dendritic cell-based in vitro model to assess Mycobacterium tuberculosis SO2 vaccine immunogenicity

View more

A human population-based organotypic in vitro model for cardiotoxicity screening

View more

A human population-based organotypic in vitro model for cardiotoxicity screening_suppl

View more

E-cigarettes and the need and opportunities for alternatives to animal testing

View more

A k-NN algorithm for predicting oral sub-chronic toxicity in the rat - Supplementary Data

View more

Simple and rapid in vitro assay for detecting human thyroid peroxidase disruption

View more

Integrating adverse outcome pathways (AOPs) and high throughput in vitro assays for better risk evaluations, a study with drug-induced liver injury (DILI)

View more

Integrating adverse outcome pathways (AOPs) and high throughput in vitro assays for better risk evaluations, a study with drug-induced liver injury (DILI)_suppl

View more

Procurement and ex-situ perfusion of isolated slaughterhouse-derived livers as a model of donors after circulatory death

View more

Procurement and ex-situ perfusion of isolated slaughterhouse-derived livers as a model of donors after circulatory death_suppl

View more

Bleeding simulation in embalmed cadavers: bridging the gap between simulation and live surgery

View more

FAQS